ORIC Pharmaceuticals Presents Preclinical and Translational Data on Rinzimetostat

ORIC presented preclinical and translational data at the ESMO Congress 2026 on rinzimetostat’s potential to enhance sensitivity to androgen receptor inhibition in prostate cancer. The results highlight EED targeting and maintained effectiveness against resistance mutations to EZH2 inhibitors such as mevrometostat.